drugset / Trial / NCT04260373

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.

NCT04260373

Phase 1 Completed 6 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]SHR4640 in Chinese healthy adult male volunteers.

Timeline

Start
2020-03-19
Primary completion
2020-04-03
Completion
2020-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR4640 Small molecule 10 mg Oral

Indications

No indication recorded.